Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients

Narbutt, Joanna; Olejniczak, Irmina; Sobolewska-Sztychny, Dorota; Sysa-Jędrzejowska, Anna; Słowik-Kwiatkowska, Iwona; Hawro, Tomasz; Lesiak, Aleksandra

doi:10.1007/s00403-012-1293-6

Cited by 65 publications

(71 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of IL-31 in the pathogenesis of diseases has been confirmed in many inflammatory dermatoses, including AD, allergic contact dermatitis and psoriasis (25,34,(39)(40)(41)(42)(43). The increased expression of IL-31 in the skin of transgenic mice correlated with intensity of skin lesions (17,44).…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Malek¹,

Gleń²,

Rębała³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS) belong to the group of primary cutaneous T-cell lymphomas (CTCL). Regardless of the stage of the disease, patients with MF and SS can suffer from chronic pruritus. The aim of the study was to investigate the correlation between the interleukin 31 (IL-31) serum level, the degree of pruritus and CTCL severity; and to compare the frequency of IL-31 gene polymorphisms between patients and the control group, and between patients at different stages of the disease. Pruritus affected 67.7% of patients with MF and SS in our study. The IL-31 serum level was significantly higher in CTCL patients than in the control group but there were no positive correlation between IL-31 serum level and pruritus. A statistically significant difference in allele frequencies for IL-31 IVS2+12 gene polymorphisms between early and advanced stages was detected; GAG haplotype was more frequent and AGA was less frequent in stage IA patients compared with patients in the other stages of the disease.

show abstract

Section: Discussionmentioning

confidence: 92%

“…In other dermatological diseases, correlation of IL-31 with disease activity has been shown in AD (40)(41)(42)(43)(44) and mastocytosis (51). This correlation has not been found in patients with psoriasis (39).…”

Section: Discussionmentioning

confidence: 96%

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Malek¹,

Gleń²,

Rębała³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Such clinical data may form an important foundation to support the evidence‐based care of psoriasis patients with itch symptoms. The following discussion reviews the itch effect of topical agents, systemics and biologics, and phototherapy, as revealed in recent studies (Table ) . Itch relief remains a significant gap in the treatment landscape for psoriasis, as not all patients are able to achieve control of this symptom, even with cleared or markedly improved skin.…”

Section: Management Of Itch In Psoriasismentioning

confidence: 99%

Itch: an under‐recognized problem in psoriasis

Elewski

Alexis

Lebwohl

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis has historically been considered a nonpruritic dermatosis, in contrast with atopic dermatitis. Thus, itch has often been underappreciated and overlooked in psoriasis. However, increasing evidence over the past decade has shown that itch can be one of the most prevalent and burdensome symptoms associated with psoriasis, affecting almost every patient to some degree. Itch can involve the entire body, although it predominantly affects the legs, hands, back, body and especially the scalp. Uncontrolled itch can significantly impact all aspects of the well‐being and quality of life of the patient. While there has been some progress in trying to better understand the pathophysiology of itch in psoriasis, more research effort and interest are needed. This under‐recognition of itch in psoriasis is clearly reflected in the dearth of treatment options targeting itch despite significant advancement in treating the lesions themselves. Recently, however, clinical studies have begun to include itch as a study outcome. The resulting data have demonstrated concomitant antipruritic benefits and improved Psoriasis Area and Severity Index (PASI) scores with mainstay treatments for psoriasis, such as topical corticosteroids and vitamin D analogs, phototherapies, and various systemics and biologics. This article takes a closer look at this debilitating symptom, reviewing the available epidemiology data for psoriatic itch, presenting the current understanding of psoriatic itch pathophysiology and highlighting important clinical data for various treatment options for itch. Practical considerations for increasing the recognition of itch as well as improving its management in psoriasis are also provided.

show abstract

“…To date there is no single antipruritic therapy dedicated specifically to treating itch in psoriasis. Recently, Narbutt et al (2012) have shown that treatment with narrowband UVB decreased the level of interleukin 31 in the sera of psoriatic patients, a finding that might explain the antipruritic effect of phototherapy. Probably, this observation will be confirmed in subsequent studies and this compound would become freely available for pruritic psoriatics in the near future.…”

Section: Treatment Of Pruritus In Psoriasismentioning

confidence: 99%